STORM
Regimen
- Experimental
- adjuvant sorafenib
- Control
- placebo
Population
Hepatocellular carcinoma after curative resection or ablation
Key finding
Median RFS 33.3 vs 33.7 mo (HR 0.940, P=0.26, NS). Sorafenib adds no adjuvant benefit after curative-intent resection/ablation. Clear negative trial.
Source: PMID 26361969
Timeline
Guideline citations
- NCCN HCC (p.49)